… These data may explain some of the observed clinical activity of HER1/EGFR inhibitors in
patients previously treated with multiple therapies. HER1/EGFR tyrosine kinase inhibitors may …

… Several tyrosine kinase inhibitors have been developed and evaluated over the past 10
years of which the majority are reversible competitors with ATP for binding to the intracellular …

… rate and safety profile of erlotinib HCl (erlotinib, Tarceva™, OSI-… Thirty-four patients received
150 mg erlotinib orally once daily … Erlotinib was generally well tolerated. The most frequent …

… Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor, … Here, we demonstrate that erlotinibinduced cell growth inhibition in EGFR high-expressing …

… HCL and a molecular weight of 429.90. Erlotinib hydrochloride is very slightly soluble in …
Aqueous solubility of erlotinib hydrochloride is dependent on pH with increased solubility at …

… gefitinib (ZD1839, Iressa ® ) [4] and erlotinib hydrochloride (OSI-774, … inhibition of the human
EGFR tyrosine kinase [6], [7]. Phase I clinical trials with single-agent erlotinib hydrochloride …

… , developed by OSI Pharmaceuticals, is an oral selective EGFR tyrosine kinase inhibitor, the
… Erlotinib hydrochloride has the molecular formula C 22 H 23 N 3 O 4 .HCl and a molecular …

… Both of the available EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) are currently
being investigated in the adjuvant setting in NSCLC, after the administration of adjuvant chemo…

… Inhibition of tyrosine kinase activity prevents HER1/EGFR phosphorylation, the associated …
in patients with relapsing NSCLC treated with Tarceva (erlotinib HCl; OSI-774). Final report of …

… Single, oral 150-mg doses of erlotinib hydrochloride in film-coated tablets were administered
with 200 ml of water either after a 10-h overnight fast (A) or within 5 min of consumption of …